Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 4:58 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 4,776 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Multiple Cancers Clear all
Completed Phase 2 Interventional

Sirolimus for Cowden Syndrome With Colon Polyposis

NCT04094675
View directory record Official record
Conditions
PTEN Gene Mutation, PTEN Hamartoma Tumor Syndrome, PTEN Hamartoma Syndrome, Cowden Syndrome, Bannayan Syndrome, Bannayan Zonana Syndrome, Polyposis
Interventions
Sirolimus
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Nov 3, 2026, 4:58 AM EST
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours

NCT02683941
View directory record Official record
Conditions
Neuroendocrine Tumors in Lung
Interventions
Lanreotide (Autogel formulation), Placebo, Best Supportive Care
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
14
States / cities
Tucson, Arizona • Los Angeles, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2022 · Synced Nov 3, 2026, 4:58 AM EST
Recruiting Not applicable Interventional

Pilot SMART of a Remotely Delivered, Physical Activity Intervention for Breast Cancer Survivors

NCT07706556
View directory record Official record
Conditions
Breast Cancer
Interventions
Affect-based Exercise Prescription, Effort-based exercise prescription, Standard Exercise Promotion Program, Step-up Exercise Promotion Program
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 3, 2026, 4:58 AM EST
Completed Phase 2 Interventional Results available

Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)

NCT01520922
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL), Leukaemia, Lymphocytic, Chronic
Interventions
Ofatumumab, Bendamustine
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
6
States / cities
Tuscon, Arizona • Aurora, Colorado • Fort Myers, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Nov 3, 2026, 4:58 AM EST
Terminated Phase 2 Interventional Results available

Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation

NCT00396383
View directory record Official record
Conditions
Multiple Myeloma
Interventions
plerixafor
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 13, 2014 · Synced Nov 3, 2026, 4:58 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

PowerUp for Health: A Diabetes Prevention Program for Men

NCT02555631
View directory record Official record
Conditions
Type 2 Diabetes, Men
Interventions
lifestyle
Behavioral
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Nov 3, 2026, 4:58 AM EST
Recruiting No phase listed Observational

Development of 3D Multi-Parametric Ultrasound (MPUS) as a Decision Support Tool for Patients

NCT05705219
View directory record Official record
Conditions
Liver Cancer, Adult
Interventions
3D-MPUS
Diagnostic Test
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Palo Alto, California • San Diego, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Nov 3, 2026, 4:58 AM EST
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer

NCT01410565
View directory record Official record
Conditions
Bladder Cancer
Interventions
Apaziquone, Placebo
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
28
States / cities
Glendale, Arizona • Phoenix, Arizona • Laguna Woods, California + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Nov 3, 2026, 4:58 AM EST
Not listed Phase 2 Interventional

Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Chemotherapy Alone in Treating Women With Stage IV Breast Cancer

NCT00012311
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, CMF regimen, carboplatin, cyclophosphamide, docetaxel, doxorubicin hydrochloride, etoposide, fluorouracil, ifosfamide, methotrexate, thiotepa, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years to 59 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Nov 3, 2026, 4:58 AM EST
Recruiting Phase 1Phase 2 Interventional

Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

NCT06303193
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
pacritinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 120 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 3, 2026, 4:58 AM EST
Completed Phase 1 Interventional

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

NCT01183663
View directory record Official record
Conditions
Advanced Cancers
Interventions
Lenalidomide, Bevacizumab, Sorafenib, Temsirolimus, Oxaliplatin, Leucovorin, 5-fluorouracil
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Nov 3, 2026, 4:58 AM EST
Recruiting Phase 1 Interventional

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

NCT06218914
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer, Solid Tumor, Adult, KRAS G12D
Interventions
NT-112: Autologous, engineered T Cells targeting KRAS G12D, AZD0240: Autologous, engineered T Cells targeting KRAS G12D
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2043
U.S. locations
18
States / cities
Duarte, California • Los Angeles, California • Newport Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 3, 2026, 4:58 AM EST
Not listed Phase 3 Interventional

Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver

NCT00039234
View directory record Official record
Conditions
Melanoma (Skin), Metastatic Cancer
Interventions
aldesleukin, histamine dihydrochloride
Biological · Drug
Lead sponsor
Maxim Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
11
States / cities
Santa Monica, California • Aurora, Colorado • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Nov 3, 2026, 4:58 AM EST
Recruiting Not applicable Interventional

The Ambient Light Multiple Myeloma Study

NCT05737732
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Circadian Effective Lighting, Circadian Ineffective Lightning (CIL)
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Nov 3, 2026, 4:58 AM EST
Completed Phase 4 Interventional

MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I

NCT01501487
View directory record Official record
Conditions
Breast Cancer
Interventions
TAC chemotherapy, TC chemotherapy, Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy, TCH chemotherapy, T + trastuzumab followed by CEF + trastuzumab, Dose dense AC followed by T + trastuzumab, Dose dense AC followed by T + trastuzumab + pertuzumab, PTH followed by dose dense AC of FEC
Drug
Lead sponsor
Agendia
Industry
Eligibility
18 Years and older · Female only
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
9
States / cities
Mobile, Alabama • Clearwater, Florida • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Nov 3, 2026, 4:58 AM EST
Completed Phase 1 Interventional Results available

Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease

NCT01949532
View directory record Official record
Conditions
Relapsed Multiple Myeloma, End-stage Renal Disease
Interventions
Carfilzomib
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Detroit, Michigan • Lake Success, New York • Canton, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Nov 3, 2026, 4:58 AM EST
Active, not recruiting Phase 2 Interventional

Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant

NCT03289299
View directory record Official record
Conditions
Smoldering Multiple Myeloma
Interventions
Carfilzomib, Lenalidomide, Daratumumab, Dexamethasone
Drug
Lead sponsor
International Myeloma Foundation
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
10
States / cities
Tampa, Florida • Chicago, Illinois • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Nov 3, 2026, 4:58 AM EST
Completed Phase 2 Interventional

Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis

NCT00676832
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Placebo, COLAL-PRED
Drug
Lead sponsor
Prometheus Laboratories
Industry
Eligibility
18 Years to 75 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
89
States / cities
Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 78 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2010 · Synced Nov 3, 2026, 4:58 AM EST
Completed Phase 1 Interventional

A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid Tumors

NCT00728793
View directory record Official record
Conditions
Tumors
Interventions
CUDC-101
Drug
Lead sponsor
Curis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Detroit, Michigan • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Nov 3, 2026, 4:58 AM EST
Active, not recruiting Phase 4 Interventional

Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

NCT02584933
View directory record Official record
Conditions
ALK Positive Malignancies
Interventions
ceritinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
5
States / cities
Fayetteville, Arkansas • Loma Linda, California • Aurora, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Nov 3, 2026, 4:58 AM EST
Completed Phase 1 Interventional

A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b

NCT02279433
View directory record Official record
Conditions
Solid Tumors
Interventions
DS6051b
Drug
Lead sponsor
Nuvation Bio Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
6
States / cities
Scottsdale, Arizona • Orange, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Nov 3, 2026, 4:58 AM EST
Terminated Phase 2 Interventional Results available

A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer

NCT04479436
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Patritumab Deruxtecan
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 100 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
21
States / cities
Fayetteville, Arkansas • Duarte, California • Aurora, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Nov 3, 2026, 4:58 AM EST
Active, not recruiting Phase 2 Interventional

Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM

NCT04009109
View directory record Official record
Conditions
Myeloma, Multiple
Interventions
Lenalidomide, Ixazomib, Daratumumab Injection, Dexamethasone
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years to 75 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Bangor, Maine • Boston, Massachusetts • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Nov 3, 2026, 4:58 AM EST
Recruiting Phase 2 Interventional

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

NCT06535607
View directory record Official record
Conditions
Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 5 Unresectable Pleural Mesothelioma (Volrustomig Monotherapy)
Interventions
Volrustomig, Cisplatin, Carboplatin, Paclitaxel, 5-FU
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Baltimore, Maryland • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Nov 3, 2026, 4:58 AM EST